Search

Your search keyword '"Ashikaga T"' showing total 17 results
Start Over Author "Ashikaga T" Database Supplemental Index
17 results on '"Ashikaga T"'

1. Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer

Author

Ades, S., Kumar, S., Alam, M., Goodwin, A., Weckstein, D., Dugan, M., Ashikaga, T., Evans, M., Verschraegen, C., and Holmes, C.E.

Abstract

Patients with metastatic colon cancer (mCRC) are at increased risk of venous thromboembolism (VTE). Limited preclinical data suggest that the oncogene (KRAS) mutational status of the tumor represents a plausible clinical link to systemic hypercoagulability in cancer patients.

Published
2015
Full Text
View/download PDF

2. Characteristics in response rates for surveys administered to surgery residents.

Author

Yarger, John B., James, T.A., Ashikaga, T., Hayanga, A.J., Takyi, V., Lum, Y., Kaiser, H., and Mammen, J.

Abstract

Background: Surveys are important research tools that permit the accumulation of information from large samples that would otherwise be impractical to collect. Resident surveys have been used frequently to monitor the quality of postgraduate training. Low response rates threaten the utility of this research tool. The purpose of this study was to determine the standard response rate of surveys administered to surgery residents and identify characteristics associated with achieving greater response rates. Methods: A search of peer-reviewed literature published between September 2003 and June 2011 was performed with the use of PubMed with Medical Subject Headings: “internship and residency,” “surgery,” “data collection,” and “questionnaires.” For inclusion, articles must have described a survey given to active surgery residents within the United States. Surveys were evaluated based on the following criteria: population size, response rate, incentive use, follow-up use, survey format (online vs paper), and institution versus national. Results: Of 433 initial results, 47 met inclusion criteria with a mean response rate of 65.3%. Surveys administered in paper format had a greater response rate compared with those given electronically (mean 78.6% vs 36.4%, respectively, P < .001). Greatest mean response rates were seen for institutional surveys compared with those given nationally (83.1% vs 42% respectively, P < .001). Conclusion: Our review demonstrated that paper surveys administered at the institutional level and during assemblies integrated into residents’ schedules demonstrated enhanced response rates. The validity and generalizability of data collected through such surveys will improve as the aspects which dictate response rate are better understood and implemented. [Copyright &y& Elsevier]

Published
2013
Full Text
View/download PDF

4. Detection of intravascular epidural catheters using 2-chloroprocaine

Author

Rathmell, J.P., Viscomi, C.M., and Ashikaga, T.

Abstract

Background and Objectives. Detecting the intravascular placement of epidural cattheters is essential to avoid local anesthetic toxicity. Small doses of intravenous local anesthetics produce changes in sensorium and are often used to test newly placed epidural catheters. Many parturients receive nalbuphine for analgesia prior to epidurla catheter placement. This study examines how nalbuphine premedication influences symptoms following intravenous 2-chloroprocaine. Methods. Thirty-one volunteers were randomized to receive premedication with placebo or 0.15 mg/kg of nalbuphine intravenously. Starting 10 minutes later, intravenous injections of 0.0, 0.3 0.6, 0.9, 1.2 and 1.5 mg/kg of 2-chloroprociane were given in random order at 10 minute intervals. After each injection volunteers were asked to report changes in hearing, taste, or other symptoms. Results. Symptoms reported (in decreasing order of frequency) were auditory changes, taste changes, dizziness/lightheadedness, tingling in the extremities, and visual changes. The probability that volunteers will report symptoms is proportional to the dose of 2-chloroprocaine administered (auditory symptoms, P<.001; taste symptoms, P=.01; any symptoms, P<.001). Nalbuphine-premedicated volunteers were more likely to report symptoms (auditory symptosms P=.004; taste symptoms, P=.004; any symptoms, P=.02). A dose of at least 1.5 mg/kg appears to be necessary to produce a 90% probability that patients will reprot symptoms when they receive 2-chloroprocaine intravenously. Conclusions. This study suggests that patients who receive nalbuphine for analgesia prior to epidural placement will be more likely to report symptoms after receiving intravenous 2-chloroprocaine during epidural test dosing.

Published
1997
Full Text
View/download PDF

9. Comparison of Indolidan Analog Binding Sites of Drug Antibody and Sarcoplasmic Reticulum with Inhibition of Cyclic AMP Phosphodiesterase

Author

Ashikaga, T., Robertson, D. W., Sportsman, R. J., Strada, S. J., and Thompson, W. J.

Abstract

Dihydropyridazinone(DHP) derivatives such as indolidan are positive inotropic agents that show inhibition of cyclic AMP phosphodiesterase(PDE) activity. Indolidan inhibition is selective for PDE3 among the seven PDE gene families. DHP derivatives and related analogs have been used to define critical regions of the active site of PDE3 isoforms and radiolabeled analogs have been used to define indolidan sarcoplasmic reticulum (SR) receptor sites. We report here studies comparing the structure-activity relationships (SAR) for PDE3 inhibition with indolidan binding to two types of sites: canine SR and a monoclonal antibody derived against indolidan conjugated to a hemocyanin. SR and monoclonal antibody binding both fit single-site, high affinity models (IC50 = 1.2 and 62 nM) that were near 52 and 360 times that of SR PDE3. Indolidan and thirteen analogs showed similar competition with either SR 3H-LY186126 binding or SR PDE3 inhibition. Antibody binding maintained selectivity but showed a different rank order potency for SR binding. Indole ring C3 methylation increased and DHP ring C4' methylation decreased indolidan monoclonal antibody binding while both substitutions increased SR binding. These studies support the hypothesis that SR PDE3 is a cardiotonic receptor site in myocardial membranes and indicate that models of the structural features of binding sites derived from inhibitor data alone could produce models with limited topography relative to the natural ligand.

Published
1996
Full Text
View/download PDF

10. TNF modulates endothelial properties by decreasing cAMP

Author

Koga, S., Morris, S., Ogawa, S., Liao, H., Bilezikian, J. P., Chen, G., Thompson, W. J., Ashikaga, T., Brett, J., Stern, D. M., and et, al.

Abstract

Tumor necrosis factor-alpha (TNF-alpha), a monokine that contributes to vascular dysfunction accompanying the host response to gram-negative sepsis, has been shown to increase vascular permeability in vivo and to diminish the barrier function of cultured endothelial cell (EC) monolayers. The studies reported here indicate that a mechanism through which TNF alters EC barrier function involves a reduction in intracellular adenosine 3',5'-cyclic monophosphate (cAMP) content, due in part to increased cyclic nucleotide phosphodiesterase (CNPDE) activities. TNF increased the diffusional transit of [3H]sorbitol, [3H]inulin, and 125I-labeled albumin across confluent bovine aortic EC monolayers. This effect of TNF was both time and dose dependent and occurred in parallel with a fall in EC cAMP. cAMP analogues, such as dibutyryl cAMP (DBcAMP), prevented TNF-induced perturbation of EC barrier function. TNF also mediated another important alteration in the EC phenotype, in that both mRNA and activity of the anticoagulant cofactor thrombomodulin were reduced after exposure of EC to TNF and were normalized by the addition of DBcAMP. EC monolayers exposed to TNF-alpha showed increased cAMP levels when exposed to 3-isobutyl-1-methylxanthine, a nonspecific CNPDE inhibitor. Ion exchange chromatography of cytosol derived from TNF-treated EC consistently showed an approximately 245% increase in phosphodiesterase (PDE) IV (high-affinity, cAMP-specific PDE) activity as identified by rolipram inhibition. PDE II activity was increased by 150% after TNF-alpha treatment of early passage EC, which was identified by cGMP-activated hydrolysis of cAMP. Western and Northern analyses, as well as activity studies, revealed that TNF treatment did not change the amount of PDE IV protein or mRNA but rather increased the specific activity of the isozyme, suggesting that a posttranslational modification had occurred. These data indicate that activation of EC CNPDE activity and decreased intracellular cAMP may represent a mechanism by which TNF increases EC permeability and promotes a procoagulant EC phenotype.

Published
1995
Full Text
View/download PDF

12. Poster session 1: Wednesday 3 December 2014, 09:00-16:00 * Location: Poster area

Author

Tong, L, Huang, C, Ramalli, A, Tortoli, P, Luo, J, D'hooge, J, Tzemos, N, Mordi, I, Bishay, T, Bishay, T, Negishi, T, Hristova, K, Kurosawa, K, Bansal, M, Thavendiranathan, P, Yuda, S, Popescu, BA, Vinereanu, D, Penicka, M, Marwick, TH, study, SUCCOUR, Hamed, W, Kamel, MKA, Yaseen, RIY, El-Barbary, HSE, Nemes, A, Kis, O, Gavaller, H, Kanyo, E, Forster, T, Angelis, A, Vlachopoulos, C, Ioakimidis, N, Felekos, I, Chrysohoou, C, Aznaouridis, K, Abdelrasoul, M, Terentes, D, Ageli, K, Stefanadis, C, Kurnicka, K, Domienik-Karlowicz, J, Lichodziejewska, B, Goliszek, S, Grudzka, K, Krupa, M, Dzikowska-Diduch, O, Ciurzynski, M, Pruszczyk, P, Gual Capllonch, F, Lopez Ayerbe, J, Teis, A, Ferrer, E, Vallejo, N, Junca, G, Pla, R, Bayes-Genis, A, Schwaiger, JP, Knight, DS, Gallimore, A, Schreiber, BE, Handler, C, Coghlan, JG, Bruno, R M, Giardini, G, Malacrida, S, Catuzzo, B, Armenia, S, Brustia, R, Ghiadoni, L, Cauchy, E, Pratali, L, Kim, KH, Lee, KJ, Cho, JY, Yoon, HJ, Ahn, Y, Jeong, MH, Cho, JG, Park, JC, Cho, SK, Nastase, O, Enache, R, Mateescu, AD, Botezatu, D, Popescu, BA, Ginghina, C, Gu, H, Sinha, MD, Simpson, JM, Chowienczyk, PJ, Fazlinezhad, A, Tashakori Behesthi, AHMAD, Homaei, FATEME, Mostafavi, H, Hosseini, G, Bakaeiyan, M, Boutsikou, M, Petrou, E, Dimopoulos, A, Dritsas, A, Leontiadis, E, Karatasakis, G, Sahin, S T, Yurdakul, S, Yilmaz, N, Cengiz, B, Cagatay, Y, Aytekin, S, Yavuz, S, Karlsen, S, Dahlslett, T, Grenne, B, Sjoli, B, Smiseth, OA, Edvardsen, T, Brunvand, H, Nasr, G, Nasr, A, Eleraki, A, Elrefai, S, Mordi, I, Sonecki, P, Tzemos, N, Gustafsson, U, Naar, J, Stahlberg, M, Cerne, A, Capotosto, L, Rosato, E, D'angeli, I, Azzano, A, Truscelli, G, De Maio, M, Salsano, F, Terzano, C, Mangieri, E, Vitarelli, A, Renard, S, Najih, H, Mancini, J, Jacquier, A, Haentjens, J, Gaubert, JY, Habib, G, Caminiti, G, D'antoni, V, D'antoni, V, Cardaci, V, Cardaci, V, Conti, V, Conti, V, Volterrani, M, Volterrani, M, Ahn, J, Kim, DH, Lee, HO, Iliuta, L, Kim, SY, Ryu, S, Ko, CW, Pyun, YS, Yoon, SJ, Lo Iudice, F, Esposito, R, Lembo, M, Santoro, C, Ballo, PC, Mondillo, S, De Simone, G, Galderisi, M, Hwang, YM, Kim, JH, Kim, JH, Moon, KW, Yoo, KD, Kim, CM, Tagliamonte, E, Rigo, F, Cirillo, T, Caruso, A, Astarita, C, Cice, G, Quaranta, G, Romano, C, Capuano, N, Calabro', R, Zagatina, A, Zhuravskaya, N, Guseva, O, Huttin, O, Benichou, M, Voilliot, D, Venner, C, Micard, E, Girerd, N, Sadoul, N, Moulin, F, Juilliere, Y, Selton-Suty, C, Baron, T, Christersson, C, Johansson, K, Flachskampf, FA, Lee, S, Lee, J, Hur, S, Park, J, Yun, JY, Song, SK, Kim, WH, Ko, JK, Nyktari, E, Bilal, S, Ali, SA, Izgi, C, Prasad, SK, Aly, MFA, Kleijn, SAK, Kandil, HIK, Kamp, OK, Beladan, CC, Calin, A, Rosca, M, Craciun, AM, Gurzun, MM, Calin, C, Enache, R, Mateescu, A, Ginghina, C, Popescu, BA, Mornos, C, Mornos, A, Ionac, A, Cozma, D, Crisan, S, Popescu, I, Ionescu, G, Petrescu, L, Camacho, S, Gamaza Chulian, S, Carmona, R, Diaz, E, Giraldez, A, Gutierrez, A, Toro, R, Benezet, J, Antonini-Canterin, F, Vriz, O, La Carrubba, S, Poli, S, Leiballi, E, Zito, C, Careri, S, Caruso, R, Pellegrinet, M, Nicolosi, GL, Kong, W, Kyu, K, Wong, R, Tay, E, Yip, J, Yeo, TC, Poh, KK, Correia, M, Delgado, A, Marmelo, B, Correia, E, Abreu, L, Cabral, C, Gama, P, Santos, O, Rahman, MT, Borges, I P, Peixoto, ECS, Peixoto, RTS, Peixoto, RTS, Marcolla, VF, Okura, H, Kanai, M, Murata, E, Kataoka, T, Stoebe, S, Tarr, A, Pfeiffer, D, Hagendorff, A, Generati, G, Bandera, F, Pellegrino, M, Alfonzetti, E, Labate, V, Guazzi, M, Kuznetsov, VA, Yaroslavskaya, EI, Pushkarev, GS, Krinochkin, DV, Zyrianov, IP, Carigi, S, Baldazzi, F, Bologna, F, Amati, S, Venturi, P, Grosseto, D, Biagetti, C, Fabbri, E, Arlotti, M, Piovaccari, G, Rahbi, H, Bin Abdulhaq, A, Tleyjeh, I, Santoro, C, Galderisi, M, Costantino, MF, Tarsia, G, Innelli, P, Dores, E, Esposito, G, Matera, A, De Simone, G, Trimarco, B, Capotosto, L, Azzano, A, Mukred, K, Ashurov, R, Tanzilli, G, Mangieri, E, Vitarelli, A, Merlo, M, Gigli, M, Stolfo, D, Pinamonti, B, Antonini Canterin, F, Muca, M, D'angelo, GA, Scapol, S, Di Nucci, M, Sinagra, G, Behaghel, A, Feneon, D, Fournet, M, Thebault, C, Martins, RP, Mabo, P, Leclercq, C, Daubert, C, Donal, E, Davinder Pal, SINGH, Prakash Chand, NEGI, Sanjeev, ASOTRA, Rajeev, MERWAH, Ankur, DWIVED, Ram Gopal, SOOD, Mzoughi, K, Zairi, I, Jabeur, M, Ben Moussa, F, Ben Chaabene, A, Kamoun, S, Mrabet, K, Fennira, S, Zargouni, A, Kraiem, S, Demkina, AE, Hashieva, FM, Krylova, NS, Kovalevskaya, EA, Potehkina, NG, Zaroui, A, Ben Said, R, Smaali, S, Rekik, B, Ben Hlima, M, Mizouni, H, Mechmeche, R, Mourali, MS, Malhotra, A, Sheikh, N, Dhutia, H, Siva, A, Narain, R, Merghani, A, Millar, L, Walker, M, Sharma, S, Papadakis, M, Siam-Tsieu, V, Mansencal, N, Arslan, M, Deblaise, J, Dubourg, O, Zaroui, A, Rekik, B, Ben Said, R, Boudiche, S, Larbi, N, Tababi, N, Hannachi, S, Mechmeche, R, Mourali, MS, Mechmeche, R, Zaroui, A, Chalbia, T, Ben Halima, M, Rekik, B, Boussada, R, Mourali, MS, Chistyakova, M V, Govorin, AV, Radaeva, EV, Lipari, P, Bonapace, S, Valbusa, F, Rossi, A, Zenari, L, Lanzoni, L, Targher, G, Canali, G, Molon, G, Barbieri, E, Novo, G, Giambanco, S, Sutera, MR, Bonomo, V, Giambanco, F, Rotolo, A, Evola, S, Assennato, P, Novo, S, Budnik, M, Piatkowski, R, Kochanowski, J, Opolski, G, Chatzistamatiou, E, Mpampatseva Vagena, I, Manakos, K, Moustakas, G, Konstantinidis, D, Memo, G, Mitsakis, O, Kasakogias, A, Syros, P, Kallikazaros, I, Park, SM, Kim, SA, Kim, MN, Shim, WJ, Marketou, M, Parthenakis, F, Kalyva, N, Pontikoglou, CH, Maragkoudakis, S, Zacharis, E, Patrianakos, A, Maragoudakis, F, Papadaki, H, Vardas, P, Rodrigues, AC, Perandini, LA, Souza, TR, Sa-Pinto, AL, Borba, E, Arruda, AL, Furtado, M, Carvalho, F, Bonfa, E, Andrade, JL, Hlubocka, Z, Malinova, V, Palecek, T, Danzig, V, Kuchynka, P, Dostalova, G, Zeman, J, Linhart, A, Chatzistamatiou, E, Konstantinidis, D, Memo, G, Mpampatzeva Vagena, I, Moustakas, G, Manakos, K, Trachanas, K, Vergi, N, Feretou, A, Kallikazaros, I, Corut, H, Sade, LE, Ozin, B, Atar, I, Turgay, O, Muderrisoglu, H, Ledakowicz-Polak, A, Polak, L, Krauza, G, Zielinska, M, Szulik, M, Streb, W, Wozniak, A, Lenarczyk, R, Sliwinska, A, Kalarus, Z, Kukulski, T, Nogueira, MA, Branco, LM, Agapito, A, Galrinho, A, Borba, A, Teixeira, PP, Monteiro, AV, Ramos, R, Cacela, D, Cruz Ferreira, R, Guala, A, Camporeale, C, Tosello, F, Canuto, C, Ridolfi, L, Chatzistamatiou, E, Moustakas, G, Memo, G, Konstantinidis, D, Mpampatzeva Vagena, I, Manakos, K, Traxanas, K, Vergi, N, Feretou, A, Kallikazaros, I, Hristova, K, Marinov, R, Stamenov, G, Mihova, M, Persenska, S, Racheva, A, Plaskota, KJ, Trojnarska, O, Bartczak, A, Grajek, S, Ramush Bejiqi, RA, Retkoceri, R, Bejiqi, H, Beha, A, Surdulli, SH, Seya, M, Sasaoka, T, Hirasawa, K, Yoshikawa, S, Maejima, Y, Ashikaga, T, Hirao, K, Isobe, M, none, Dreyfus, J, Durand-Viel, G, Cimadevilla, C, Brochet, E, Vahanian, A, Messika-Zeitoun, D, Jin, CN, Fang, F, Meng, FX, Kam, K, Sun, JP, Tsui, GK, Wong, KK, Wan, S, Yu, CM, Lee, AP, Cho, I J, Chung, HM, Heo, R, Ha, SJ, Hong, GR, Shim, CY, Chang, HJ, Ha, JW, Chung, N, Moral, S, Gruosso, D, Galuppo, V, Teixido, G, Rodriguez-Palomares, JF, Gutierrez, L, Evangelista, A, Moral, S, Gruosso, D, Galuppo, V, Teixido, G, Rodriguez-Palomares, JF, Gutierrez, L, Evangelista, A, Moral, S, Gruosso, D, Galuppo, V, Teixido, G, Rodriguez-Palomares, JF, Gutierrez, L, Evangelista, A, Alexopoulos, Alexan, Dawson, David, Nihoyannopoulos, Petros, Zainal Abidin, H A, Ismail, JOHAN, Arshad, KAMAL, Ibrahim, ZUBIN, Lim, CW, Abd Rahman, E, Kasim, SAZZLI, Peteiro, J, Barrio, A, Escudero, A, Bouzas-Mosquera, A, Yanez, J, Martinez, D, Castro-Beiras, A, Scali, MC, Simioniuc, A, Mandoli, GE, Lombardo, A, Massaro, F, Di Bello, V, Marzilli, M, Dini, FL, Adachi, H, Tomono, J, Oshima, S, Merchan Ortega, G, Bravo Bustos, D, Lazaro Garcia, R, Sanchez Espino, AD, Macancela Quinones, JJ, Ikuta, I, Ruiz Lopez, MF, Valencia Serrano, FM, Bonaque Gonzalez, JC, Gomez Recio, M, Romano, G, D'ancona, G, Pilato, G, Di Gesaro, G, Clemenza, F, Raffa, G, Scardulla, C, Sciacca, S, Lancellotti, P, Pilato, M, Addetia, K, Takeuchi, M, Maffessanti, F, Weinert, L, Hamilton, J, Mor-Avi, V, Lang, RM, Sugano, A, Seo, Y, Watabe, H, Kakefuda, Y, Aihara, H, Nishina, H, Ishizu, T, Fumikura, Y, Noguchi, Y, Aonuma, K, Luo, XX, Fang, F, Lee, APW, Shang, Q, Yu, CM, Sammut, E C, Chabinok, R, Jackson, T, Siarkos, M, Lee, L, Carr-White, G, Rajani, R, Kapetanakis, S, Byrne, D, Walsh, JP, Ellis, L, Mckiernan, S, Norris, S, King, G, Murphy, RT, Hristova, K, Katova, TZ, Simova, I, Kostova, V, Shuie, I, Ferferieva, V, Bogdanova, V, Castelon, X, Nemes, A, Sasi, V, Domsik, P, Kalapos, A, Lengyel, C, Orosz, A, Forster, T, Grapsa, J, Demir, O, Dawson, D, Sharma, R, Senior, R, Nihoyannopoulos, P, Pilichowska, E, Zaborska, B, Baran, J, Stec, S, Kulakowski, P, Budaj, A, Herrera, J E, Palacios, I F, Mendoza, I, Marquez, J A, Herrera, J A, Octavio, J A, Dempaire, G, Rotolo, M, Kosmala, W, Kaye, G, Saito, M, Negishi, K, Marwick, TH, Maceira Gonzalez, A M, Ripoll, C, Cosin-Sales, J, Igual, B, Salazar, J, Belloch, V, Dulai, R S, Taylor, A, and Gupta, S

Abstract

Purpose: We have previously demonstrated that multi-line transmit (MLT) beam forming can provide high quality full field-of-view (90° sector) B-mode images at very high frame rates, i.e. up to 500 fps. The purpose of this study was to test the feasibility of this technique in imaging the mechanical intraventricular waves such as the one associated with activation of the left ventricle. Methods: A dedicated pulse sequence using MLT was implemented on the ULA-OP research scanner equipped with a 2.0 MHz phased array to obtain 90° sector images at a frame rate of 436 fps. The left ventricle of a healthy volunteer was imaged from the apical 4 chamber view and the RF data was acquired. Subsequently, the strain rate was extracted from the RF data using a normalized cross-correlation method. Results: As expected, during the early filling phase, myocardium lengthening (positive strain rate) was observed propagating from the base of the septum to the apex and back (Figure a). A similar wave was detected in the lateral wall, although a brief shortening (negative strain rate) was detected in the mid-wall which could be the result of reverberations (Figure b). During isovolumetric contraction, the septal wall shortened before the lateral wall (as expected) - moreover - there seemed to be an intra-wall base-apex shortening gradient (Figure c and d). Conclusions: Our preliminary results show that visualization of the cardiac mechanical activation could be feasible using MLT based high frame rate imaging. Further research is required to examine this in depth, which is the topic of on-going work. Figure Curved M-mode of strain rate

Published
2014
Full Text
View/download PDF

15. Topically Administered Acyclovir in the Treatment of Recurrent Herpes Simplex Genitalis: A Controlled Trial

Author

Reichman, R. C., Badger, G. J., Guinan, M. E., Nahmias, A. J., Keeney, R. E., Davis, L. G., Ashikaga, T., and Dolin, R.

Abstract

Eighty-eight patients with culture-proven recurrent herpes simplex genitalis were entered into a collaborative, randomized, placebo-controlled, double-blind trial to evaluate the efficacy and toxicity of a topical formulation of acyclovir. Patients entered the study within 48 hr of the onset of lesions, and the study medication was applied six times daily for five days. The duration of virus shedding from lesions present at the time of entry into the study was significantly reduced for men who received acyclovir compared with men who received placebo (P <0.05). There were no significant differences between the acyclovir- and placebo-treated groups of either sex in time to crusting of lesions, time required for lesions to heal, time to cessation of pain, or in frequency with which new lesions developed during the course of therapy. Mild, transient burning or pain associated with application of the study medication was a common complaint.

Published
1983
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results